CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals TEVA regarding the Firdapse (amifampridine) patent litigation.
Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.
Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva
Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock was recently at $22.
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases,
Catalyst stock climbs 15% on Firdapse litigation settlement
Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva (TEVA) that would delay the launch of a generic version of its drug Firdapse until at least 2035.
HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 ...
Zacks.com on MSN3d
Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Catalyst Pharmaceuticals (NASDAQ:CPRX) Given Buy Rating at Bank of America
Bank of America reissued their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research ...
Hosted on MSN3d
Here's Why Momentum in Catalyst (CPRX) Should Keep going
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...
bovnews3d
Analysts Predict a $35 Target for Catalyst Pharmaceuticals Inc (CPRX) Stock—What Could Drive It There?
Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...
Catalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating with 58.7% Upside Potential
Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...